Pivotal studies indicated that glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) stimulate mice progenitor cells to proliferate and differentiate into insulin‐secreting cells [22], highlighting the therapeutic potential of these medications in T1D (i.e., adjuvant treatment in islet transplantation) [23]. Here, INS is linked to type 1 diabetes mellitus.